TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: MRI findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diagnosis/prediction of heart disease outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Elevation or decrease of mRNAs miR Let-7i, miR-16 and miR-92
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in MEP Amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optimal negative pressure threshold value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metastases to bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Metastases to lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Diagnostic image quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in cardiac structure and function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Depression Score for Caregiver
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: percentage of relative renal function of the obstructed kidney
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: reduction of patient's management cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: visual acuity at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: visual function at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of subjects with clinically significant changes in 12-lead electrocardiogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Performance on tests of hemispatial neglect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spatial working memory performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tests of motor control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants achieving ECP-defined treatment goals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of inhaled sodium pyruvate
Endpoint domain: Adverse events/effects
Primary endpoint: Endoscopic Healing Rate of Duodenal Ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Degree of myocarditis evaluated by cardiac MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of Hip Joint Function measured by Harris Hip Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ISQ measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathologic Complete Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline sit to stand 10 test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact of IBD on Diabetes Mellitus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: bacterial count from skin swabs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number and Severity of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Virologic response at Week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Major obstetric haemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Subjects With at Least 4-fold Increase in Anti-Vi ELISA Titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-Vi ELISA Geometric Mean Concentration (GMC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maternal Death
Endpoint domain: Mortality/survival
Primary endpoint: Transfusion of Packed Red Blood Cells
Endpoint domain: Adverse events/effects
Primary endpoint: Change in glutamate and glutamine (GLX)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Presence or absence of intra-pituitary cystic lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean changes in fasting plasma glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean changes in post-glucose administration plasma glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean changes in blood HbA1c values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Nerve functional evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Depressive and Anxiety Symptoms (CES-D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blinded rating of the treatment area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of serum glutamic oxalacetic transaminase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Change of serum glutamic-pyruvic transaminase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Instrumental swallowing evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of chronic postsurgery pain
Endpoint domain: Adverse events/effects
Primary endpoint: Change in HADS anxiety score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in HADS depression score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: HCO3-
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity as assessed by NCI CTCAE v3.0
Endpoint domain: Adverse events/effects
Primary endpoint: Level of Lipocalin-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of Semaphorin 3A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infectious Dose-50 based on infection rate after challenge with various doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of serious adverse events related to virus challenge
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects with GII.2 Snow Mountain norovirus-associated illness following GII.2 challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Controlled Oral Word Association Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: DMF index (Decayed, Missing, Filled)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Intraocular Pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Fecal probiotic (KE-99) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hypovolemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of Pelvic Organ Prolapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apnea Hypopnea Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Arousal Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygen Desaturation Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Capture of Outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: the ability of daily living
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: the length of hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: the rehospitalization rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Yale Brown Obsessive Compulsive Scale Modified for Pathological Gambling (YBOCS-PG)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Faces Pain Scale-Revised (FPSR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mean Trough Sitting Diastolic Blood Pressure (SiDBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants Who Experience ≥1 Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Dose Limiting Toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Objective Response Rate of Participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of MET mutation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Identification of TP53 mutation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Presence of MET and HER2 amplification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prevalence of drug allergy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of grade 3/4 neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Exercise VO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise HR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Last Unformed Stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of patients with MRI abnormality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-report Visual Analog Ratings of HIGH
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-report Visual Analog Ratings of DRUG EFFECT
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Successful Surface Anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose Tolerability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Positive and Negative TSH Test Result
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Concentration of TSH in Whole Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cervical dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Overall Objective Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Gluteus Medius Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Endometrial line thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacologic induction of PVD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Mean Sitting Diastolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pro and anti-inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treprostinil pharmacokinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: General functioning status
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in cognitive test scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Evidence of Chronic Ongoing Synovial-Based Inflammatory Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Safety and tolerability from reported adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of episodes of loss of control and/or binge eating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Change in Exhaled Nitric Oxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to first heart failure hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composite adverse event rate
Endpoint domain: Adverse events/effects
Primary endpoint: Objective Tumor Response Rate (CR or PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of Adverse Effects Grade 3 or Greater
Endpoint domain: Adverse events/effects
Primary endpoint: Specificity of the algorithm for detecting valve disease and congenital heart disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Activities-specific Balance Confidence scale (ABC)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Dose limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Cluster of differentiation (CD)8+ T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Score on a Visual Analogical Scale (VAS) for actual pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugl Meyer Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Wolf Motor Function Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Metabolic Stress Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent improvement in Psoriasis Area and Severity Index (PASI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Pulmonary capacity changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Days to reach the titration target
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Primary Major Adverse Cardiac Events (MACE)
Endpoint domain: Adverse events/effects
Primary endpoint: Confirmed tumor response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Tracer uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Circulating indicators of cholesterol homeostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Brain physiological activity correlation to sleep states
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Characterization of sleep-wake behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional impact of STN-DBS on sleep-wake behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in HBV DNA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 18F-MPPF binding potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: levels of urine phthalate metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of Joint Hypermobility / hypermobile Ehlers-Danlos Syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apnea-Hypopnea Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: ECGs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of volunteers with moderate and greater severity clinical adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of volunteers who report willingness to use the study regimen
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean intracellular drug concentration for each group assigned to FTC/TDF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of volunteers who took at least 80% of expected doses of the IP
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Walking Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical evaluation outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trunk Neuromuscular Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients with grade ≥ 3 toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: NYHA status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: tiredness/fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Inter-reader variability of myocardial viability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: DE CT image quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of cured patients
Endpoint domain: Mortality/survival
Primary endpoint: Number of patients with treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with esophageal varices and low platelet count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: number of units and types of blood transfusions up to 24 hours after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: anticipated vs. actual blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hemoglobin/hematocrit values prior to surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Healing (migration) of tuberculum majus and minus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: implantation rate of the embryo
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Length of hospital stay after surgery
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Successful nasal allergen challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serious adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Change in actigraphic sleep quality
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in parent reported sleep problems
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in child reported sleep and eating problems
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in Radiographic Measurements of Bone Ridge Dimensions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Patient's pain score post-procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Clinical laboratory test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vital sign
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Healthy Participants Reporting Mild-to-Moderate Influenza Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time until therapeutic failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants Achieving a Viral Load Reduction of at Least 0.5 Log 10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Behavior Rating Inventory of Executive Function-Preschool Version
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Return to play (recovery period)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Correlation between Delta SUVmax and Delta ADCmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With ACR20 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Malondialdehyde
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tibial Blood Perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in quality of visual life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in treatment choice
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Reduction in pruritus severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lipid Necrotic Core (LNC) in mm²
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intra Plaque Hemorrhage (IPH) in mm²
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fibrous Cap Ulceration (FCU) in mm²
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in tumor burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes